Abstract

Background : Statins (HMG-CoA Inhibitors) is a drug used for decreasing plasma cholesterol levels and used in therapy to prevent coronary artery disease. Research in animals and epidemiological studies showed that statin therapy can decrease risk against cancer associated with cholesterol. Based on that result then research of cytotoxic activity against simvastatin knowing cultur T47D breast cancer cells and his influence in decreasing expression of cyclin D1 and induction of apoptosis has been done. Research objectives : The aims of this research is to prove activities of simvastatin against T47D breast cancer cell culture, especially to examine cytotoxic activity, cyclin D1 expression, and simvastatin effect in apoptotic induction. Research method : The type of this research is quasi experiment with using posttest with non-equivalent control group design. Cytotoxicity test performed on T47D breast cancer cell cultures using MTT assay to determine IC 50 values after given simvastatine. Expression of cyclin D1 and apoptosis induction test detected using flow cytometry with antibody monoclonal anti-cyclin D1 and Annexin V-Pi, then analyzed by FACS-Calibur program. Results : Simvastatin has cytotoxic effect against T47D breast cancer cells with IC 50 values 25.25 µg/mL. Simvastatin with concentrations of 6.31; 12.62; 25.25 and 50.5 µg/mL was able to decrease the cyclin D1 expression. Furthermore, simvastatin can induce apoptosis with EC 50 values 26.96 µg/mL in T47D breast cancer cells. Conclusion : Simvastatin has cytotoxic activity of in T47D breast cancer cells and decreasing cyclin D1 expression and inducing apoptosis activity in T47D breast cancer cells. Keywords: simvastatin, cytotoxic, cyclin D1, apoptotic, T47D.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.